Related Experiment Video
Updated: Jul 16, 2025
Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
Published on: March 18, 2019
Cardiac tissue engineering for the treatment of hypoplastic left heart syndrome (HLHS)
Rebecca Abraham1, Luca Vricella2,3, Narutoshi Hibino2,3
1Medical Scientist Training Program, University of Chicago, Chicago, IL, USA.
Insights
Stem cell therapies show promise for treating hypoplastic left heart syndrome (HLHS), a severe congenital heart defect. Clinical trials indicate safety and feasibility, with potential for cardiac tissue regeneration and improved heart function in HLHS patients.
Area of Science:
- Regenerative Medicine
- Cardiology
- Developmental Biology
Background:
- Hypoplastic left heart syndrome (HLHS) is a critical congenital heart defect characterized by underdevelopment of the left ventricle and outflow tract.
- Current treatments for HLHS primarily involve palliative surgeries creating a single-ventricle physiology, with heart transplantation as the only definitive option.
- Significant unmet needs exist for HLHS, driving research into novel therapeutic strategies.
Purpose of the Study:
- To explore the potential of stem cell-based regenerative therapies for HLHS.
- To evaluate the safety and efficacy of pluripotent cell introduction in HLHS patients.
- To review pre-clinical advancements in cardiac tissue engineering for HLHS treatment.
Main Methods:
- Review of clinical trials involving pluripotent cell transplantation in the heart.
- Analysis of pre-clinical research on cardiac patch development using engineered tissues.
- Assessment of stem cell therapy's impact on cardiac function, specifically right ventricular ejection fraction (RVEF).
Main Results:
- Clinical trials demonstrate that introducing pluripotent cells into the heart is safe and feasible.
- These stem cell interventions have shown capability in improving right ventricular ejection fraction (RVEF) in HLHS patients.
- Pre-clinical studies are advancing the creation of larger, more complex cardiac tissues for potential cardiac repair.
Conclusions:
- Stem cell-based regenerative therapies hold significant promise for improving HLHS treatment.
- Further development in cardiac tissue engineering could lead to robust, long-lasting cardiac repair strategies.
- Stem cell therapies offer a potential avenue to enhance current management of hypoplastic left heart syndrome.
Abstract:
Hypoplastic left heart syndrome (HLHS) is a deadly congenital heart disease that arises when the left ventricle and outflow tract fail to develop appropriately, inhibiting the adequate perfusion of the rest of the body. Historically, this disease has been treated via a series of surgeries that allows the heart to use a single ventricle. These surgeries are often a palliative measure, and heart transplantation is the only definitive therapy that exists for this condition. It has been hypothesized that stem cell-based regenerative therapies could have a role in promoting cardiac tissue regeneration in HLHS patients who are undergoing palliative surgery. Several clinical trials have demonstrated that introducing pluripotent cells into the heart is safe, feasible, and capable of improving right ventricular ejection fraction (RVEF). However, while these approaches show great promise, there is still room for development. There is a substantial body of pre-clinical work that is focused on generating increasingly large and complex pieces of cardiac tissue in the form of cardiac patches, with the idea that these could be used to rebuild and strengthen the heart in a robust and long-lasting manner. In total, stem cell-based therapies have much to offer when it comes to improving the treatment of HLHS.
